With profound expertise in antibody engineering, payload design, linker development, and conjugation strategies, BOC Sciences has established a one-stop ADC early discovery solution platform. We provide not only commercial antibody screening and customized development services but also cover linker synthesis, payload selection, conjugation optimization, and comprehensive analytical and characterization support, fully facilitating the discovery and optimization of candidate molecules. Through flexible project docking mechanisms and a professional R&D team, BOC Sciences can swiftly respond to customer demands, accelerate ADC development processes, and offer strong technical support for the R&D of next-generation targeted therapeutics.
During the early discovery phase, issues such as insufficient antibody affinity or undefined conjugation sites are common. BOC Sciences offers engineered antibody screening and site-specific modification technologies to ensure both antibody functionality and compatibility with conjugation sites.
Many cytotoxic payloads suffer from poor solubility or are difficult to modify. BOC Sciences maintains a diverse payload library and supports functional group optimization and prodrug design to enhance conjugation compatibility and stability.
Linkers must remain stable in the bloodstream while releasing efficiently at the target site. BOC Sciences provides a range of enzyme-sensitive, reduction-sensitive, and innovative smart linker strategies to meet various release mechanism requirements.
ADC conjugates often exhibit DAR variability and structural heterogeneity. BOC Sciences possesses a well-established conjugation platform and high-throughput analytical systems to rapidly screen for highly stable and active ADC candidates.
Leveraging its deep technical accumulation in bioconjugation, chemical synthesis, protein engineering, and structural optimization, BOC Sciences has built a highly efficient and flexible early discovery service system. This covers several key steps, including antibody screening, payload selection, linker design, and conjugation strategy development. Our goal is to help clients rapidly construct well-defined, highly developable ADC candidate molecules, thus accelerating downstream development timelines.
In addition to R&D support, BOC Sciences offers comprehensive analytical and biocharacterization services to evaluate critical quality attributes (CQAs) during ADC development. This helps clients fully control molecular structure, purity, conjugation site distribution, and functional activity, laying a solid foundation for subsequent development.
Clients may flexibly choose individual services such as antibody screening, payload design, linker development, or conjugation optimization, or opt for a fully integrated one-stop solution that precisely matches diverse project requirements.
Built-in resources for both commercial and experimental payloads and linkers enable rapid structural screening and combination validation, accelerating the identification of promising ADC candidates.
Covers various conjugation processes including lysine-based random conjugation, cysteine-specific site-directed conjugation, click chemistry, and enzymatic conjugation to meet diverse conjugation needs while ensuring high homogeneity.
Equipped with advanced analytical instruments and multi-dimensional biocharacterization technologies to support comprehensive evaluation of key quality attributes such as conjugation efficiency, DAR value, purity, and biological activity.
With standardized workflows and a professional team, preliminary constructs and analytical reports can be delivered within 2–4 weeks, significantly accelerating R&D progress and efficiency.
Customized confidentiality agreements and service contracts ensure strict control over data and outcome ownership, providing strong security for customer project confidentiality and result exclusivity.
In-depth discussion with clients regarding project background, target information, and technical requirements to formulate customized research plans.
Services include antibody screening, custom development, humanization, tagging, or conjugation site engineering to meet construction needs.
Based on efficacy and stability requirements, appropriate linker/toxin combinations are selected and validated from a comprehensive library.
Selection and application of suitable conjugation strategies (e.g., site-specific/non-specific, chemical/enzymatic conjugation) for ADC candidate construction.
Systematic evaluation of key attributes such as conjugation efficiency, DAR value, purity, stability, and in vitro bioactivity.
Delivery of comprehensive analytical reports and constructs, along with ongoing technical consultation and extended development support.
We offer one-stop services including antibody screening and engineering, linker and payload selection, conjugation strategy development, construct preparation, and supporting analytical characterization.
Yes. By adjusting conjugation conditions, site engineering, and linker structures, we can help optimize DAR values and enhance construct stability and activity.
We do not provide direct target discovery services, but we can support literature mining and antibody screening based on client-provided target information to rapidly generate antibody candidates for further engineering and conjugation.
Absolutely. Our platform supports modular service integration, allowing clients to select individual elements such as linker screening, payload pairing, or conjugation optimization as needed for each project stage.
Our platform supports multiple conjugation methods including lysine conjugation, cysteine reduction conjugation, site-directed engineering conjugation, click chemistry, and enzymatic conjugation to accommodate various strategic requirements.
Yes. We can conduct parallel screening of multiple antibodies, payloads, and linkers to improve construct efficiency and expedite the identification of optimal ADC candidates.
